TNG961 / Tango Therap - LARVOL DELTA

TNG961: A selective oral molecular glue degrader of HBS1L for the treatment of FOCAD-deficient cancers (AACR 2026) - "IND-enabling studies are complete with a clean safety profile supporting a starting dose within the active range. These data establish targeted degradation of HBS1L as a novel therapeutic approach for FOCAD-deficient cancers and expand the landscape of actionable vulnerabilities arising from 9p21 tumor-suppressor loss."

Oncology • CDKN2A • CDKN2B • CRBN • MTAP

TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers. (PubMed, Cancer Discov) - "Guided by cryo-EM structures and proteome selectivity we developed TNG961, a potent, selective HBS1L degrader that disrupts the HBS1L/PELO complex, inducing translational arrest, unfolded protein response activation, and growth inhibition in FOCAD-negative models. Oral administration of TNG961 regresses FOCAD-negative xenografts, including PRMT5 inhibitor-refractory models, establishing HBS1L degradation as a strategy to exploit FOCAD loss and supporting clinical evaluation of TNG961 as a first-in-class precision oncology therapeutic."

Journal • Oncology • Targeted Protein Degradation • CDKN2A • CRBN • MTAP

TNG961: A selective oral molecular glue degrader of HBS1L inducing tumor regression in naïve and PRMT5i-refractory FOCAD-deleted models (AACR-NCI-EORTC 2025) - "Notably, TNG961 remains effective in a pancreatic model that has become refractory to PRMT5 inhibitor treatment, supporting its potential utility in PRMT5i-resistant settings. TNG961 has been nominated as a development candidate and is currently in IND-enabling studies."

Oncology • CDKN2A • CDKN2B • CRBN • GSPT1 • MTAP • SALL4